Uncertainty surrounding potential US tariffs is threatening to disrupt India's booming pharma deal market, according to Rothschild & Co. While short-term M&A activity may slow due to a lack of confidence and predictability, the industry remains resilient in the long run.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/u4w5GE3
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» Tariff risks cloud near-term pharma deals outlook: Rothschild's Stefano Beschi
0 comments:
Post a Comment